Clinical Trial

Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma.

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 22, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the safety and tolerability and determine the recommended phase 2/phase 3 dose of RAD regimen in PCNSL
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2020-12-24; most recent amendment 2025-05-19.
Status change: Recruiting → Active, Not Recruiting 2025-05-19
Status change: Not Yet Recruiting → Recruiting 2023-11-08
Trial Details
NCT Number NCT04688151
Lead Sponsor National Health Research Institutes, Taiwan
Collaborators: National Taiwan University Hospital, National Cheng-Kung University Hospital, China Medical University Hospital, Chang Gung Memorial Hospital
Conditions Primary Central Nervous System Lymphoma (PCNSL)
Enrollment 22 participants
Start Date 2021-02-22
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-22